MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.neuropharm.2026.111190

Медицинская библиотека · Neuropharmacology · 2026

Behavioral and molecular effects of α2A-adrenergic receptor activation in the triple-hit Lisket rat model of schizophrenia.

Horvath Gyongyi, Plesz Szonja Bianka, Ducza Eszter, Szatmári Peter, Solymos Emese, Nyári Tibor, Kekesi Gabriella

СтатьяПеревод в очереди

Аннотация

Dysregulation of the noradrenergic system has been implicated in the pathophysiology of schizophrenia. Although α2-adenergic receptor (α2-AR) agonists may alleviate positive symptoms, their effects on cognitive and negative symptoms remain controversial. This study aimed to characterize the dose-dependent effects of repeatedly administered α2A-AR agonist, guanfacine, on behavioral activity, cognition, and cerebral α2A-AR mRNA expression in male Long Evans rats and their schizophrenia-like substrain (Lisket). Animals received guanfacine (0.02; 0.1, and 0.5 mg/kg intraperitoneally) or vehicle for 11 days. Behavioral performance was assessed using the reward-based Ambitus test before treatment and during treatment (days 8-11). Guanfacine produced dose-dependent impairments following an inverted-U pattern in several exploration- and cognition-related parameters particularly in Lisket animals. However, guanfacine did not influence the number of collected rewards, attention-related parameters, reference memory, or overall data variability. Vehicle treated Lisket rats showed reduced α2A-AR mRNA expression in the prefrontal cortex and increased expression in the brainstem and a similar trend in the hippocampus compared with controls. Guanfacine produced region-specific effects, including decreased prefrontal and increased subcortical α2A-AR expression. These findings provide new insights into the expression of cerebral α2A-AR mRNA in a complex schizophrenia model and subsequent effects of guanfacine. They reveal that this compound has a detrimental or ineffective impact on behavioral outcomes. The results highlight the complexity of noradrenergic modulation in schizophrenia and suggest that α2A-AR agonist therapy alone is unlikely to alleviate cognitive or negative symptoms associated with the disorder. This emphasizes the need for more integrative therapeutic strategies that target multiple neuromodulator systems.

Для цитирования: Horvath Gyongyi, Plesz Szonja Bianka, Ducza Eszter, Szatmári Peter, Solymos Emese, Nyári Tibor, Kekesi Gabriella. Behavioral and molecular effects of α2A-adrenergic receptor activation in the triple-hit Lisket rat model of schizophrenia.. Neuropharmacology. 2026. DOI: 10.1016/j.neuropharm.2026.111190.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.